Does dyslipidemia affect diabetes control in type 2 diabetic patients?

被引：0
|
作者：
Kyriazis, I. A.
Zervas, E.
Mytas, D.
Stougianos, P.
Lalousis, A.
Michas, D.
Paraskevopoulos, K.
Pirgakis, V.
Partheniou, Ch.
机构：
[1] Korinthos Gen Hosp, Lipid Outpatient Clin, Korinthos, Greece
[2] Korinthos Gen Hosp, Diabet Outpatient Clin, Korinthos, Greece
[3] Korinthos Gen Hosp, Dept Internal Med, Korinthos, Greece
[4] Korinthos Gen Hosp, Dept Cardiol, Korinthos, Greece
来源：
ATHEROSCLEROSIS SUPPLEMENTS | 2007年 / 8卷 / 01期
关键词：
D O I：
10.1016/S1567-5688(07)71359-4
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
引用
收藏
页码：103 / 103
页数：1
相关论文
共 50 条
  • [31] The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus
    Rosenblatt, S
    Miskin, B
    Glazer, NB
    Prince, MJ
    Robertson, KE
    CORONARY ARTERY DISEASE, 2001, 12 (05) : 413 - 423
  • [32] Improved glucose control is not adequate to treat dyslipidemia in urban patients with type 2 diabetes
    Cook, CB
    Erdman, DM
    Gallina, DL
    Ziemer, DC
    Dunbar, VG
    DIABETES, 2000, 49 : A266 - A266
  • [33] Dyslipidemia in type 2 diabetes
    Krauss, RM
    Siri, PW
    MEDICAL CLINICS OF NORTH AMERICA, 2004, 88 (04) : 897 - 909
  • [34] Poorer glycemic control is associated with dyslipidemia in type 2 diabetes
    Brown, JB
    Nichols, GA
    Hayes, RP
    Bowman, L
    DIABETES, 2004, 53 : A227 - A228
  • [35] Poorer glycemic control is associated with dyslipidemia in type 2 diabetes
    Nichols, GA
    Brown, JB
    Hayes, RP
    Bowman, L
    DIABETOLOGIA, 2004, 47 : A13 - A13
  • [36] The relation between nephropathy and dyslipidemia in Type 2 diabetic patients
    Nakhjavani, M
    Behjati, J
    Esteghamati, A
    Esfahanian, F
    Aghamohamadzadeh, N
    Abbasi, M
    DIABETOLOGIA, 2004, 47 : A388 - A388
  • [37] Prevalence of microvascular complications in type 2 diabetic patients with dyslipidemia
    Zeryouh, N.
    Messaoudi, N.
    Benyakhlef, S.
    Laalaoua, Y.
    Hamdane, C.
    Rouf, S.
    Latrech, H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [38] Dyslipidemia and serum cystatin C levels as biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus
    Dejenie, Tadesse Asmamaw
    Abebe, Endeshaw Chekol
    Mengstie, Misganaw Asmamaw
    Seid, Mohammed Abdu
    Gebeyehu, Natnael Atnafu
    Adella, Getachew Asmare
    Kassie, Gizchew Ambaw
    Gebrekidan, Amanuel Yosef
    Gesese, Molalegn Mesele
    Tegegne, Kirubel Dagnaw
    Anley, Denekew Tenaw
    Feleke, Sefineh Fenta
    Zemene, Melkamu Aderajew
    Dessie, Anteneh Mengist
    Moges, Natnael
    Kebede, Yenealem Solomon
    Bantie, Berihun
    Adugna, Dagnew Getnet
    FRONTIERS IN ENDOCRINOLOGY, 2023, 14
  • [39] Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in type 2 diabetic patients with hypertension
    Kuriyama, Genshin
    Mori, Yutaka
    Itoh, Yohta
    Tajima, Naoko
    DIABETES, 2006, 55 : A121 - A122
  • [40] Association of Dyslipidemia with Diabetic Retinopathy in Type 2 Diabetes Mellitus Patients: A Hospital-Based Study
    Ezhilvendhan, Kalaimamani
    Sathiyamoorthy, Anitha
    Prakash, B. Jey
    Bhava, B. Saravana
    Shenoy, Arjun
    JOURNAL OF PHARMACY AND BIOALLIED SCIENCES, 2021, 13 (06): : S1062 - S1067
12345